THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Ozempic, known generically as semaglutide, is an injectable prescription drug. It was approved in 2017 by the United States ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.